Scholars Central

Conference abstractPublished 21 Nov 2018

Orphan medicines and paediatric drug development

Authors: Mette Due Theilade Thomsen

Managing Director, PIP Adviser, Copenhagen, Denmark

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A significant proportion of orphan medicines designations are for products that receive marketing authorisation for use in children; some 60% of designated orphan medicines in Europe are intended for paediatric use. In Europe, a paediatric investigation plan (PIP) for the medicine under development will need to be agreed with the European Medicines Agency before a marketing authorisation application can be validated - unless paediatric drug development can be waived for the condition in question. Medicines authorised across the EU with the results of studies from a paediatric investigation plan included in the product information are eligible for an extension of their supplementary protection certificate. For designated orphan medicines, the incentive is an additional two years of market exclusivity. The presentation will go through the regulatory requirements for developing an orphan medicinal product intended for the paediatric population. This will be supplied with case examples.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Mette Due Theilade Thomsen”